Royalty Pharma says Elan sale process seeks to deflect Royalty bid
(Reuters) - Royalty Pharma believes that the only reason Elan Corp Plc (ELN.I) has announced a sales process is to deflect Royalty's own offer, the company's CEO said in a statement Friday morning.
Royalty Pharma has not heard from Elan or its financial advisers, said Pablo Legorreta, Royalty's chief executive officer, in the e-mailed statement.
"If shareholders want to have the option to choose between Royalty Pharma's offer or a sale process, they should vote against all four of Elan's proposals, especially the share repurchase program," the firm said in its statement.
(Reporting By Jessica Toonkel; Editing by Gerald E. McCormick)
NEW YORK - Stocks slipped on Tuesday, a day after a record close on the S&P 500, with traders looking ahead to next week's Federal Reserve meeting in the absence of market-moving economic data.
WASHINGTON - U.S. small business sentiment bounced back from a seven-month low in November, with owners setting their sights on creating more jobs and expanding operations.
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.